Description
Alluvi Tirzepatide 20mg is a dual-agonist research peptide targeting GLP-1 and GIP receptors. This formulation is widely used in comparative studies and metabolic research protocols.
Key Features:
• Dual agonist (GLP-1 and GIP receptors)
• 20mg per pen
• 4 doses of 5mg each
• Once-weekly injection schedule
• Alluvi Healthcare manufacturing
• Pharmaceutical-grade purity
• 12 disposable needles included
Research Advantages:
Tirzepatide’s dual-agonist mechanism offers a different profile compared to triple agonists, making it valuable for:
• Comparative receptor studies
• Metabolic research protocols
• Body composition studies
• Glucose regulation investigations
• Longevity research applications
Administration:
Subcutaneous injection only. Pre-measured doses ensure consistent administration. Refrigerate at 2°C to 8°C. Each dose is ready for immediate use.
Research Community:
Tirzepatide has become a standard reference compound in peptide research, allowing researchers to compare triple-agonist effects against dual-agonist mechanisms.
⚠️ Research Disclaimer:
This product is intended for research purposes only. It is not intended for human consumption or medical use. Always consult with qualified professionals before use.
